Journals / Genel Tıp Dergisi / 2006 / Cilt: 16 - Sayı: 4

Use of in vivo probe drugs in the determination of activities of drug metabolizing enzymes

İlaç metabolizmasında rol oynayan enzimlerin aktivitelerinin belirlenmesinde in vivo prob ilaç kullanımı

Pages
203–211
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Probe drugs have the potential use in clinical pharmacology and toxicology studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this review, the knowledge was given about the use of in vivo probe drugs in the determination of drug metabolizing enzyme activities.
📊
Key Findings & Data:Inter-individuals and ethnics variability have been demonstrated in the pharmacokinetics and pharmacodynamics of many drugs and in susceptibility to toxic substances because of variations in the expression of different enzymes in tissues.
💡
Conclusion & Impact:Conclusion: Probe drugs have the potential use in clinical pharmacology and toxicology studies.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Enzim aktivasyonu · Fenotip · Biyobelirteçler

Abstract

Objective: In this review, the knowledge was given about the use of in vivo probe drugs in the determination of drug metabolizing enzyme activities. Main findings: Drug metabolizing enzymes play an important role in the biotransformation of various xenobiotics. Inter-individuals and ethnics variability have been demonstrated in the pharmacokinetics and pharmacodynamics of many drugs and in susceptibility to toxic substances because of variations in the expression of different enzymes in tissues. A wide range of methods for the determination of enzyme activities is available. These can be divided into those concerned with phenotype determination, either by measurement of enzyme levels (direct) or use of in vivo probe drugs (indirect) and genotyping methods. Because of some limitations of genotyping and direct methods, probe drugs are often used in the determination of enzyme activities. Use of in vivo probe drugs is important for evaluations of several aspects of clinical pharmacology and toxicology such as pharmacokinetic variability, individual dosage regimen, drug interactions, drug toxicity and the susceptibility to xenobiotics and for the determination of metabolic capacities of organs expressing enzymes. Conclusion: Probe drugs have the potential use in clinical pharmacology and toxicology studies.

Özet

Amaç: Bu derlemede, ilaç metabolizmasında rol oynayan enzimlerin aktivitelerinin belirlenmesinde in vivo prob ilaçların kullanımları hakkında bilgi verilmiştir. Ana bulgular: İlaç metabolizmasında görevli enzimler çeşitli ksenobiyotiklerin biyotransformasyonunda da önemli rol oynar. Dokularda enzim sentezindeki farklılıklara bağlı olarak çoğu ilacın farmakokinetik ve farmakodinamiğinde ve toksik maddelere duyarlılıkta bireylerarası ve etnik farklılıklar gösterilmiştir. Enzim aktivitelerinin belirlenmesinde kullanılan birçok metot vardır. Bunlar, enzim düzeylerinin ölçülmesi (direkt) ve in vivo prob ilaç kullanımı (indirekt) ile fenotipin belirlenmesi ve genotipik metotlar olarak ayrılabilir. Genotipik ve direkt metotların bazı sınırlamaları olduğu için enzim aktivitesinin belirlenmesinde sıklıkla prob ilaçlar kullanılır. İn vivo prob ilaç kullanımı farmakokinetik farklılık, bireysel dozaj rejimi, ilaç etkileşimleri, ilaç toksisitesi ve ksenobiyotiklere duyarlılık gibi klinik farmakoloji ve toksikoloji yönünden ve enzimlerin sentezlendiği organların metabolik kapasitelerinin belirlenmesi açısından önemlidir. Sonuç: Prob ilaçlar, klinik farmakoloji ve toksikoloji alanındaki çalışmalarda kullanılabilme potansiyeline sahiptir.

🔖

Cite This Article

ÜNEY, K., TRAŞ, B. (2006). Use of in vivo probe drugs in the determination of activities of drug metabolizing enzymes. Genel Tıp Dergisi, Cilt: 16 - Sayı: 4, 203–211. https://ajindex.com/articles/225103

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clinica Chimica Acta 2002;315:137-55
  2. Morley K. Pharmacogenetics and pharmacogenomics. Office of public policy and ethics institute for molecular bioscience; September 2002;6, Australia
  3. Daly AK. Development of analytical technology in pharmacogenetic research. Naunyn Schmiedebergs Arch Pharmacol 2004;369:133-40
  4. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997;37:40S-8S
  5. Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10:187-216
  6. Schmitz G, Aslanidis C, Lackner KJ. Pharmacogenomics: implications for laboratory medicine. Clinica Chimica Acta 2001;308:43-53
  7. Campbell NRC, Dunnette JH, Mwaluko G, van Loon J, Weinshilboum RM. Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metabolism. Clin Pharmacol Ther 1984;35:55-63
  8. Price RA, Spielman RS, Lucena AL, van Loon JA, Maidak BL, Weinshilboum RM. Genetic polymorphism for human platelet thermostable phenol sulfotransferase (TS PST) activity. Genetics 1989;122:905-14
  9. Hallier E, Langhof T, Dannappel D, Leutbecher M, Schroder K, Goergens HW et al. Polymorphism of glutathione conjugation of methyl bromide, ethylene oxide and dichloromethane in human blood: Influence on the induction of sister chromatid exchanges (SCE) in lymphocytes. Arch Toxicol 1993;67:173-8
  10. Seidegard J, Pero RW. The hereditary transmission of high glutathione transferase-activity towards trans-stilbene oxide in human mononuclear leukocytes. Hum Genet 1985;69:66-8
  11. Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL et al. Human lymhocyte cytochrome P450 2E1: A putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 1985;25:1429-35
  12. Ford LT, Berg JD. Determination of thiopurine S-methyltransferase activity in erythrocytes using 6-thioguanine as substrate and a non-extraction liguid chromatographic technique. J Chromatogr B 2003;798:111-5
  13. Carrillo, JA, Christensen M, Ramos SI, Alm C, Dahl M, Benitez J et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 2000;22:409-17
  14. Cholerton S, Idle ME, Vas A. Comparison of a novel thin-layer chromatographic-fluorescence d